slides · global inventory
Disclaimer
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 41,127
Current window 38,551-38,580
Pages 1,371
Rows per page 30
Component
38,551-38,580 of 41,127
02
Adagio Therapeutics | Investor Conference Presentation Deck | 19 slidesAdagio Therapeutics | Investor Conference Presentation Deck | 19 slides · Adagio Therapeutics
Conference presentation Investor relations 1 hit
05
The slide uses a phylogenetic tree and a dot plot to compare neutralization potency (IC50) across different viral strains.Adagio Therapeutics | Investor Conference Presentation Deck | 19 slides · Adagio Therapeutics
Conference presentation Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
06
The slide contrasts cocktail-based strategies (colored dots) with a single broadly neutralizing antibody (black dots) against various SARS-related coronaviruses.Adagio Therapeutics | Investor Conference Presentation Deck | 19 slides · Adagio Therapeutics
Conference presentation Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
07
The slide uses a heatmap to visualize IC50 values, where red indicates higher potency (lower IC50).Adagio Therapeutics | Investor Conference Presentation Deck | 19 slides · Adagio Therapeutics
Conference presentation Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
08
The table uses a color-coded heatmap to represent IC50 values, with red indicating higher potency (lower IC50).Adagio Therapeutics | Investor Conference Presentation Deck | 19 slides · Adagio Therapeutics
Conference presentation Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
09
The slide includes a disclaimer about the lack of head-to-head trials and the investigational status of ADG20.Adagio Therapeutics | Investor Conference Presentation Deck | 19 slides · Adagio Therapeutics
Conference presentation Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
10
The table uses color-coding to represent IC50 potency, with red indicating higher potency (lower IC50) and grey indicating lower potency.Adagio Therapeutics | Investor Conference Presentation Deck | 19 slides · Adagio Therapeutics
Conference presentation Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
11
The table uses a color-coded scale to represent potency (IC50), where red indicates higher potency (lower IC50) and white/grey indicates lower potency.Adagio Therapeutics | Investor Conference Presentation Deck | 19 slides · Adagio Therapeutics
Conference presentation Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
12
The slide includes a disclaimer about the lack of head-to-head trials and the investigational status of ADG20.Adagio Therapeutics | Investor Conference Presentation Deck | 19 slides · Adagio Therapeutics
Conference presentation Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
13
The table uses a color-coded scale to represent IC50 potency, with red indicating high potency (low IC50) and grey indicating low potency (high IC50).Adagio Therapeutics | Investor Conference Presentation Deck | 19 slides · Adagio Therapeutics
Conference presentation Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
14
The table uses a color-coded heatmap where red indicates higher potency (lower IC50 values) and yellow/white indicates lower potency. Includes disclaimers about lack of head-to-head trials.Adagio Therapeutics | Investor Conference Presentation Deck | 19 slides · Adagio Therapeutics
Conference presentation Investor relations Beat · Agitate (Make it worse)Loop · Cost Of Inaction1 hit
15
The slide uses a process flow diagram to illustrate clinical trial cohorts, randomization, and primary endpoints.Adagio Therapeutics | Investor Conference Presentation Deck | 19 slides · Adagio Therapeutics
Conference presentation Investor relations Beat · Solution (Provide relief)Loop · Jobs To Be Done1 hit
20
The chart illustrates a gradual shift in revenue contribution from the Americas to EMEA and APJ.Snowflake | Investor Presentation Deck | 26 slides · Snowflake
Pitch deck Investor relations Beat · TractionLoop · Quick Win Big Bet1 hit
21
The table highlights the trend of improving margins and cash flow as the company scales.Snowflake | Investor Presentation Deck | 26 slides · Snowflake
Pitch deck Investor relations 1 hit
22
Snowflake | Investor Presentation Deck | 26 slidesSnowflake | Investor Presentation Deck | 26 slides · Snowflake
Pitch deck Investor relations 1 hit
23
The table provides a detailed breakdown of stock-based compensation and amortization of acquired intangibles as adjustments to GAAP figures.Snowflake | Investor Presentation Deck | 26 slides · Snowflake
Pitch deck Investor relations 1 hit
24
The table details adjustments for stock-based compensation, amortization of intangibles, and acquisition-related expenses.Snowflake | Investor Presentation Deck | 26 slides · Snowflake
Pitch deck Investor relations 1 hit
25
Includes reconciliation for operating income, free cash flow, and adjusted free cash flow.Snowflake | Investor Presentation Deck | 26 slides · Snowflake
Pitch deck Investor relations 1 hit
26
Includes detailed footnotes regarding data definitions and sources.Snowflake | Investor Presentation Deck | 26 slides · Snowflake
Pitch deck Investor relations 1 hit
01
Includes company logos and a date.Xometry | Mergers and Acquisitions Presentation Deck | 23 slides · Xometry
Deck Investment bank 1 hit
02
Xometry | Mergers and Acquisitions Presentation Deck | 23 slidesXometry | Mergers and Acquisitions Presentation Deck | 23 slides · Xometry
Deck Investment bank 1 hit
04
Xometry | Mergers and Acquisitions Presentation Deck | 23 slidesXometry | Mergers and Acquisitions Presentation Deck | 23 slides · Xometry
Deck Investment bank 1 hit
08
Slide 8 of the deck.Xometry | Mergers and Acquisitions Presentation Deck | 23 slides · Xometry
Deck Investment bank Loop · Why Now1 hit
12
Xometry | Mergers and Acquisitions Presentation Deck | 23 slidesXometry | Mergers and Acquisitions Presentation Deck | 23 slides · Xometry
Deck Investment bank Loop · Why Now1 hit
14
Xometry | Mergers and Acquisitions Presentation Deck | 23 slidesXometry | Mergers and Acquisitions Presentation Deck | 23 slides · Xometry
Deck Investment bank Loop · Why Now1 hit
16
Xometry | Mergers and Acquisitions Presentation Deck | 23 slidesXometry | Mergers and Acquisitions Presentation Deck | 23 slides · Xometry
Deck Investment bank Loop · Why Now1 hit
19
Xometry | Mergers and Acquisitions Presentation Deck | 23 slidesXometry | Mergers and Acquisitions Presentation Deck | 23 slides · Xometry
Deck Investment bank Loop · Why Now1 hit
21
Xometry | Mergers and Acquisitions Presentation Deck | 23 slidesXometry | Mergers and Acquisitions Presentation Deck | 23 slides · Xometry
Deck Investment bank 1 hit
22
The slide uses a grid of 8 big-number metrics to provide a snapshot of company performance.Xometry | Mergers and Acquisitions Presentation Deck | 23 slides · Xometry
Deck Investment bank 1 hit
23
The table provides a breakdown of non-cash and non-recurring items such as depreciation, stock-based compensation, and impairment charges.Xometry | Mergers and Acquisitions Presentation Deck | 23 slides · Xometry
Deck Investment bank 1 hit